؉ CD25 high T cells are overrepresented in metastatic lymph nodes (LNs) with a 2-fold increased frequency compared with both tumor-free LNs and autologous PBMCs. These cells express the Foxp3 transcription factor, display an activated phenotype, and display a polyclonal TCR V␤ chain repertoire. They inhibit in vitro the proliferation and cytokine production of infiltrating CD4 ؉ CD25 ؊ and CD8 ؉ T cells (IL-2, IFN-␥) through a cell-contact-dependent mechanism, thus behaving as T reg . In some cases, the presence of T reg type 1/Th3-like lymphocytes could also be demonstrated. 
M
elanoma is considered as an important immunogenic tumor model because of the well-known occurrence of spontaneous regressions (1) , the identification of numerous tumor-associated Ags (2) , as well as the detection of Agexperienced antitumor-specific T cells in vivo (3) . Attempts to induce specific antitumoral T cell responses through various immunotherapeutic protocols have revealed the potential of vaccination in inducing in some cases regression of large tumor burden. However, such favorable outcomes are still limited and await further analysis of correlations between antitumor T cell responses and clinical improvement (4 -9) . The reasons behind the limited success of these approaches are still largely unknown. It is possible that the induced T cell responses are not the most appropriate in terms of quantity, differentiation, or capacity to home tumor sites. In contrast, the tumor itself may have developed immune escape strategies, including impairment of Ag presentation or secretion of immunosuppressive molecules like IL-10 or TGF-␤ (10). However, the in vivo nature of such a T cell counteractive microenvironment remains largely unknown.
The recent description of thymic-derived CD4
ϩ CD25 high regulatory T cells (T reg ) 3 (3) in rodents revealed their critical role in immune tolerance and the control of autoimmunity. These T reg are able to inhibit harmful autoimmune T cells in a contact-dependent and cytokine-independent mechanism (11) (12) (13) (14) . Consequently, these cells might also impair antitumor immune responses that are known to be directed at least partly against autoantigens expressed by the tumor cells (2, 3) . Indeed, recent evidence for such a role has been reported in transplantable murine tumor models, where tumor rejection was increased upon elimination of CD4 ϩ CD25 high T cells (15) (16) (17) . This population of T reg have been shown recently to express Foxp3, a forkhead/winged helix transcription factor that is disrupted in Scurfy mouse and in the human immune dysregulation polyendocrinopathy enteropathy X-linked syndrome, both lacking CD4 ϩ CD25 high T reg . Foxp3 appears critical for the development and function of T reg (18 -21) . Besides Foxp3-expressing T reg , other subsets of T reg , such as T reg type 1 (Tr1) or Th3 cells, could be generated under specific induction protocols and possibly during the course of immune responses. These subsets of T reg appear to exert their suppressive activity in a contact-independent and cytokine-dependent mechanism (22, 23) . It is not yet known whether these cells express the Foxp3 transcription factor. In humans, Foxp3 expressing CD4 ϩ CD25 high T cells similar to the rodent thymic-derived CD4 ϩ CD25 high T reg have been recently described among PBMCs and thymocytes (24 -33) . The involvement of such CD4 ϩ CD25 high T reg in cancer patients was recently questioned by different groups. Some of them studied T reg from PBMCs of colorectal cancer or melanoma patients (34 -36) , while others suggested the presence of these cells among tumor-infiltrating lymphocytes in breast, ovarian, and lung cancer, and more recently in Hodgkin lymphoma (37) (38) (39) (40) . However, the possible implication of CD4 ϩ CD25 high T reg in down-regulating antitumor responses, which could explain the poor clinical response of cancer patients under immunotherapeutic protocols, remains to be demonstrated.
In the present study, we investigated the idea that T reg could be involved in the control of the local immune response in human metastatic melanoma. We found that the frequency of CD4 ϩ CD25 high T cells is clearly increased in metastatic lymph nodes (LNs) compared with tumor-free satellite LNs and autologous PBMCs. These tumorinfiltrating CD4 ϩ
CD25
high T cells express the Foxp3 transcription factor, display a phenotype of activated memory T cells, and inhibit in vitro the proliferation and cytokine production of autologous infiltrating CD4 ϩ
Ϫ as well as CD8 ϩ T cells in a cell-contact-dependent manner. Thus, our data provide the first evidence that CD4 ϩ CD25 high T cells infiltrating human metastatic melanoma LNs behave as previously described CD4 ϩ CD25 high T reg . In addition, we found that distinct subsets of T reg may also operate locally.
Materials and Methods

Patients and samples
Twelve patients undergoing curative resections for LN metastatic melanoma before any immunotherapy or chemotherapy were included in this study after informed consent following human ethics committee procedures (Comité Consultatif pour la Protection des Personnes dans les Recherches Biomédicales; Hôpital Saint-Louis, Paris, France). Cancer stage was gathered according to the American Joint Committee on Cancer (41) (see Table I ). Peripheral blood and LNs were collected at the time of surgery. Diagnosis of metastatic LNs was obtained by histological examination and immunochemical staining with PS100 and HMB45 Abs. LNs with large tumor invasion as well as LNs with no or minimal tumor invasion (corresponding to micrometastasis or only sinusal invasion by tumor cells) could be obtained. Blood samples from healthy donors were obtained from the Etablissement Français du Sang (Hôpital Saint-Louis). LN cell suspensions, obtained after sterile mechanical dissociation, were filtered, washed, and cryopreserved for further analysis.
Abs and flow cytometric analysis
The following Abs were used: PE anti-CD25 (M-A251), allophycocyanin anti-CD28 (CD28.2), allophycocyanin anti-CD69 (L78), allophycocyanin anti-CTLA-4(BN13), allophycocyanin anti-CD45RO (UCHL1), biotinylated anti-cutaneous lymphocyte-associated Ag (HECA-452), biotinylated anti-CD45RA (HI100), allophycocyanin anti-HLA-DR (Tü36), and PerCP streptavidin (all from BD Pharmingen, San Diego, CA). We also used: FITC anti-CD4 (clone S3.5; Caltag Laboratories, Burlingame, CA) and allophycocyanin anti-CD27 Abs (O323; eBioscience, San Diego, CA). Anti-CCR7 and anti-CXCR5 were kindly provided by Dr. M. Lipp (Max-Delbrück-Centrum, Berlin, Germany). For CTLA-4 intracellular staining, the Cytofix/Cytoperm kit was used according to the manufacturer recommendations (BD Pharmingen). Lymphocytes were gated according to their forward and size scatter characteristics, and four-color FACSCalibur analysis was performed using the CellQuest software (BD Biosciences, San Jose, CA). 
Purification of CD4
Cytokines production
ELISA was used according to manufacturer recommendations (OptEIA; BD Pharmingen) to detect IL-2, IL-4, IL-10, TGF-␤ 1 , and IFN-␥ in supernatants of T cell cultures after 5 days of allogeneic stimulation or 3 days of anti-CD3/anti-CD28 stimulation. The minimal levels of detection were 3.9 pg/ml for IL-2, IL-4, and IL-10, 2.3 pg/ml for IFN-␥, and 31.2 pg/ml for TGF-␤ in four-time diluted supernatants.
Quantitative real-time PCR
RNA were first purified using the RNeasy kit (Qiagen, Carlsbad, CA), and oligo(dT) or random hexanucleotide-primed first strand cDNAs were synthesized using SuperScript II reverse transcriptase (Invitrogen Life Technologies). They were then used as a template for real-time PCR, with the TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA). Specific primers for Foxp3 and human hypoxanthine ribosyltransferase 1 (HPRT) were used with the following TaqMan MGB probe (Assays-ondemand gene expression assays; Applied Biosystems): 5Ј-6FAM-ATCCGCT GGGCCATCCTGGAGGCTC-3Ј (FoxP3), and 5Ј-6FAM-GGTCAAGGT CGCAAGCTTGCTGGTG (HPRT). Because sequences for the specific unlabelled PCR primers were not provided by the manufacturer, the realtime PCR products for Foxp3 were controlled by sequencing analysis, using an ABI Prism 3700 detection system (Applied Biosystems). Realtime PCR was conducted in a GeneAmp 5700 detection system (Applied Biosystems), with the following cycling conditions: 10 min at 95°C, followed by 40 cycles of 15 s at 95°C, and 1 min at 60°C. The mean values from duplicates were used for calculations. Data are expressed as normalized expression obtained by dividing the relative cDNA level for each sample by the relative cDNA level of HPRT for the same sample, where HPRT ϭ 1.
T cell repertoire diversity
TCR V␤ chain repertoire of sorted infiltrating CD4 ϩ CD25 high and CD4 ϩ CD25 Ϫ T cells was analyzed by quantitative Immunoscope (Applied Biosystems), as previously described (42, 43) . cDNAs obtained after reverse transcription of total RNA with oligo(dT) 17 and SuperScript II reverse transcriptase (Invitrogen Life Technologies) were amplified with each of 24 TCR V␤ subfamily-specific primers and a nested fluorochromelabeled TaqMan probe for TCR C␤. Real-time PCR was conducted in a GeneAmp 5700 detection system (Applied Biosystems). PCR products were used as templates in run-off reactions using a nested TCR C␤ fluorescent primer producing labeled ssDNA fragments that were separated on a denaturing 6% acrylamide gel on a 373 DNA sequencer (Applied Biosystems) and analyzed with Immunoscope software (42) .
Statistical analysis
Statistical analysis was performed using paired or unpaired Student's t tests with the Kaleidagraph software (Synergy Software, Reading, PA).
Results
Overrepresentation of CD4 ϩ CD25 high in metastatic melanoma LNs
Because regulatory CD4 ϩ T cell activity has been identified in the CD4 ϩ CD25 high T cell subpopulation in human PBMCs and thymocytes (24, 25, 27, 28, 30 -33) , we first estimated the proportion of such CD4 ϩ CD25 high T cells among lymphocytes infiltrating metastatic LNs in melanoma patients. Our study included 12 patients suffering from stage III melanoma before any treatment other than curative surgical resection (Table I) . Isolated lymphocytes were gated to estimate the proportion of CD4 ϩ T cells that expressed high level of CD25 (IL-2R ␣-chain) and lower level of CD4 as previously described for CD4 ϩ CD25 ϩ T reg (Fig. 1A ). The frequency of CD4 ϩ CD25 high T cells among CD4 ϩ T cells was 11.06 Ϯ 1.7% (mean Ϯ SD) in metastatic LNs (range 8.3-14.05%; n ϭ 13). We also studied tumor-free LNs and found that the frequency of CD4 ϩ CD25 high T cells was 6.2 Ϯ 4.2% (n ϭ 16). A global comparison between metastatic LNs and tumor-free LNs revealed almost a 2-fold increased frequency in metastatic LNs ( p ϭ 0.0006). The frequency of CD4 ϩ CD25 high T cells in metastatic LNs was also significantly increased when compared with the frequency observed in autologous PBMCs (4.9 Ϯ 1.9%, range 2.6 -8.7%, n ϭ 8, p Ͻ 0.0001) or in healthy donor PBMCs (5.8 Ϯ 1.7%, range 3-8.2%, n ϭ 10, p Ͻ 0.0001). No statistical difference was found between frequencies of CD4 ϩ CD25 high T cells in PBMCs from metastatic melanoma patients and healthy donors ( p ϭ 0.37). When performing matched sample analysis (i.e., comparing metastatic LNs with either PBMCs or tumor-free LNs from the same patient), the difference remained highly significant ( p ϭ 0.014 and p ϭ 0.016, respectively).
Altogether, these results revealed that the proportion of CD4 ϩ CD25 high T cells is clearly increased in metastatic LNs compared with tumor-free LNs and autologous PBMCs.
Infiltrating CD4 ϩ CD25 high T cells display a memory and activated phenotype
The majority of CD4 ϩ CD25 high T cells in 11 metastatic LNs from 10 patients expressed CD45RO (73.2 Ϯ 11.8%) and few were CD45RA positive (18.9 Ϯ 8.5%). They all expressed CD27 and CD28 molecules (Fig. 1B) and were mostly CCR7 negative (87 Ϯ 6.3%). Thus, most of these CD4 ϩ CD25 high T cells belong to the CD45RA Ϫ /CD27 ϩ conventional memory CD4 ϩ T cell population as defined by Campbell and colleagues (44) . Few expressed HLA-DR (6.6 Ϯ 2.5%) or the cutaneous homing molecule cutaneous lymphocyte-associated Ag (13.1 Ϯ 11.2%), and the great majority were CXCR5 negative (95 Ϯ 4.7%) (Fig. 1B , and data not shown). As reported for human circulating T reg , the majority of infiltrating CD4 ϩ CD25 high T cells intracellularly expressed the CTLA-4 molecule. However, more CD4 ϩ CD25 high T cells expressed CTLA-4 in metastasis (75.5 Ϯ 15.8%) compared with autologous PBMCs (48.9 Ϯ 15%) and their levels of expression were significantly higher (mean fluorescence intensity (MFI) ϭ 44 Ϯ 26 vs 15 Ϯ 8, respectively, p ϭ 0.01) (Fig. 1C) . Furthermore, surface expression of CTLA-4 was found on LN-infiltrating CD4 ϩ CD25 high T cells (4.5 Ϯ 2.4%), but not on their circulating counterparts (0.7 Ϯ 0.35%). Such an intracellular and surface upregulation of CTLA-4 has been reported for human T reg after activation in vitro (28) (41) . Disease intervals between the removals of the primary cutaneous melanoma and of the metastatic LNs are given. For two patients (SLM6 and SLM19), the primary cutaneous lesion was not evidenced. For another one (SLM18) the primary melanoma and the metastatic LNs were discovered concomitantly. patients, we found that infiltrating CD4 ϩ CD25 high T cells highly expressed Foxp3 while CD4 ϩ CD25 Ϫ T cells expressed very low levels (Fig. 2) . The levels of Foxp3 expression in CD4 ϩ CD25 high T cells from metastatic LNs compared with autologous or healthy donor PBMCs were almost similar (Fig. 2) . In three tumor-free LNs from different patients, CD4 ϩ CD25 high T cells also expressed Foxp3 (data not shown). Altogether, these data revealed that CD4 ϩ CD25 high T cells infiltrating metastatic melanoma as well as tumor-free LNs express the Foxp3 transcription factor, strongly suggesting that this population includes T reg . ϩ T cells, and tested them in in vitro proliferation assays. In all the nine metastatic LNs tested from six different patients, the sorted CD4 ϩ CD25 high T cells proliferated poorly and did not produce IL-2 or IFN-␥ in response to allogeneic stimulation (Figs. 3, A, D, and E) , thus exhibiting an anergic profile similar to what has been described for human T reg (24, 25, 27, 28, 30 -33) . In contrast, CD4 ϩ CD25 Ϫ T cells proliferated vigorously and produced both IL-2 and IFN-␥ in response to allogeneic stimulation (Fig. 3, A and D, and data not shown) .
Infiltrating
Importantly, the proliferation of CD4 ϩ CD25 Ϫ T cells was strongly inhibited in a dose-dependent manner when cocultured with CD4 ϩ CD25 high T cells (Fig. 3, A and B) . five cases where all ratios were tested (Fig. 3, A and B) . In addition, CD4 ϩ CD25 high T cells strongly inhibited IL-2 and IFN-␥ production of CD4 ϩ CD25 Ϫ T cells (Fig. 3D , and data not shown) corresponding to a 95.5 Ϯ 6.6% of inhibition for IL-2 and 98.6 Ϯ 3.8% for IFN-␥ at a 1:1 ratio. It is noteworthy that at 1:8 or 1:10 ratios, which almost correspond to the ratios observed in metastatic LNs, the inhibition of cytokine production was still major (ϳ90% inhibition; Fig. 3C , and data not shown), while the inhibition of proliferation was weaker (ϳ30% inhibition; Fig. 3A ). This suggests that infiltrating CD4 ϩ CD25 high T cells may be more suppressive on T cell functions than on T cell proliferation. In four metastatic LNs, the suppressive activity of CD4 ϩ CD25 high T cells was also tested at a 1:1 ratio against sorted infiltrating CD8 ϩ T cells. Although these cells proliferated to a lower extent than CD4 ϩ CD25 Ϫ T cells in response to allogeneic stimulation, their proliferation was also strongly inhibited by CD4 ϩ CD25 high T cells in a dose-dependent manner with a median percentage of inhibition of 62% at a 1:1 ratio (Fig. 3B, and data not shown) . Similarly, the IFN-␥ production of CD8 ϩ T cells was also strongly inhibited by CD4 ϩ CD25 high T cells (Fig. 3E) , with a median percentage of inhibition of 85% at a 1:1 ratio. In two LNs with minimal tumor invasion, the inhibition of proliferation of both CD4 ϩ CD25 Ϫ and CD8 ϩ T cells was weak, around 50% at 1:1 ratio (data not shown). In addition, as expected from recent studies on murine LNs (46), CD4 ϩ CD25 high T cells isolated from four tumor-free LNs from three different patients also displayed some suppressive activity, albeit not as potent as in metastatic LNs, because suppression was not detected at a lower ratio than 1:2 or 1:4 (Fig. 3C) .
Taken together, CD4 ϩ CD25 high T cells infiltrating melanoma metastatic LNs, and to a lesser extent tumor-free LNs, suppressed in vitro the proliferation and cytokine production of both infiltrating CD4 ϩ CD25 Ϫ as well as CD8 ϩ T cells.
Suppression by tumor-infiltrating CD4 ϩ CD25 high T cells is mediated through a cell contact mechanism
Although controversial, the mechanism of action of human CD4 ϩ CD25 high T reg appears to be largely cell contact dependent (24, 25, 27, 28, 30 -33 ). The role of cytokines, like IL-10 or TGF-␤, as well as cell surface molecules, like CTLA-4 or GITR, is still a matter of debate (14) . Therefore, we investigated whether infiltrating CD4 ϩ CD25 high T cells inhibited cell proliferation in vitro through a cell-contact-and/or cytokine-dependent mechanism. Transwell experiments performed in four metastatic LNs revealed that CD4 ϩ CD25 high T cells required cell contact to suppress proliferation of CD4 ϩ CD25 Ϫ T cells, because in all cases the inhibition of proliferation was either completely or partially abolished by the transwell (Fig. 4A, and data not shown) . Preincubation of CD4 ϩ CD25 high T cells with blocking anti-IL-10 or anti-TGF-␤ 1-3 Abs significantly reverted the suppression in experiments performed in three cases, while isotype control blocking mAbs did not (Fig. 4A, and data not shown) . As control, the preincubation of CD4 ϩ CD25 Ϫ T cells alone with these blocking Abs did not affect their proliferation (data not shown). Thus, the suppressive activity of LN-infiltrating CD4 ϩ CD25 high T cells was found to be both contact and cytokine dependent. Interestingly, we found that preincubation of infiltrating CD4 ϩ CD25 high T cells with blocking anti-CTLA-4 Ab also significantly reverted the suppression (Fig. 4A) . In all the cases tested, the anti-GITR Ab did not significantly alter the suppressive activity of the CD4 ϩ CD25 high T cells (Fig. 4A ). Finally and as previously described (27, 30 -32) , addition of IL-2 (50 or 100 IU/ml) allowed CD4 ϩ CD25 high T cells to proliferate and abolished their suppressive activity (data not shown).
Therefore, CD4 ϩ CD25 high T cells infiltrating melanoma metastatic LN suppress CD4 ϩ CD25 Ϫ T cells in a cell-contact-and CTLA-4-dependent mechanism. In addition, a cytokine-dependent mechanism could also be involved.
Tumor-infiltrating CD4
ϩ CD25 high but also CD4 ϩ CD25
Ϫ T cells secrete IL-10 and/or TGF-␤
Because the suppressive activity of CD4 ϩ CD25 high T cells was abolished by anti-IL-10 or anti-TGF-␤ 1-3 blocking Abs, we investigated whether infiltrating CD4 ϩ CD25 high and CD4 ϩ CD25 Ϫ T cells indeed produced these cytokines upon in vitro stimulation. We found that CD4 ϩ CD25 high T cells from metastatic LNs with large tumor invasion produced IL-10 upon allogeneic stimulation (36.6 up to 279.2 pg/ml; mean, 110.8 pg/ml), while in cases of minimal tumor invasion such a production was not detected (Fig.  4B) . Because in these latter cases a lower level of inhibition of CD4 ϩ CD25 Ϫ T cell proliferation was also observed compared with more advanced disease, this suggests that IL-10 production may be correlated to the strength of suppression detected in vitro (Figs. 3B and 4B) . However, stronger TCR-mediated stimulation using coated anti-CD3 and soluble anti-CD28 Abs revealed that these cells also displayed the capacity to secrete IL-10 (data not shown). In contrast, infiltrating CD4 ϩ CD25 Ϫ T cells also secrete IL-10 (27.9 up to 265.9 pg/ml; mean, 130.9 pg/ml) upon allogeneic stimulation, mostly in case of large tumor invasion (Fig. 4B) . In tumor-free LNs, we similarly observed that both CD4 ϩ CD25 high and CD4 ϩ CD25 Ϫ T cells could produce IL-10, albeit at slightly lower levels (mean, 84 and 69 pg/ml, respectively).
In few cases, infiltrating CD4 ϩ CD25 high T cells and CD4 ϩ CD25 Ϫ T cells were found to produce TGF-␤ 1 at a substantial level (Ͼ2000 and up to 8500 pg/ml) (Fig. 4C) . In the case of minimal tumor invasion, such a TGF-␤ 1 secretion was not observed and could not be induced by stimulation with anti-CD3 and anti-CD28 Abs (data not shown). Finally, TGF-␤ 1 production was not detected when analyzing T cells from tumor-free LNs (data not shown).
The fact that infiltrating CD4 ϩ CD25 Ϫ T cells secreted IL-10 and/or TGF-␤ 1 suggested that they may also display some suppressive activity. Indeed, when tested functionally in coculture experiments with infiltrating CD8 
CD25
Ϫ T cells did not produce IL-4 upon stimulation (data not shown), the presence of Th2 cells is unlikely.
Tumor-infiltrating CD4 ϩ CD25 high T cells display a largely polyclonal TCR V␤ (TCRBV) repertoire
It has been largely described in mice and humans that oligoclonality of TCR usage and characteristic features of complementaritydetermining regions 3 (CDR3) regions may reveal Ag-expanded T cells in a given T lymphocyte population even if the Ag is not known (47) . Thus, to obtain insight into the potential Ag-driven expansion of CD4 ϩ CD25 high T cells infiltrating melanoma metastatic LNs, we performed a detailed Immunoscope analysis of their TCRBV repertoire by, first, quantifying the BV family usage through real-time PCR, and, second, by determining their CDR3␤ chain length distributions through Immunoscope analysis (42, 43) . We found that both CD4 ϩ CD25 high and CD4 ϩ CD25 Ϫ T cell populations from three metastatic LNs from different patients and from one tumor-free LN expressed an highly diverse set of BV families and that these populations differed quantitatively only on a limited number of BV families for a given patient. Similar results were obtained for the four LNs studied and a representative case is shown in Fig. 5A . In each case, including the tumor-free LN, similar BV families (as BV15, 20, or 23, for example) were poorly or not detected in both CD4
ϩ CD25 high and CD4 ϩ CD25 Ϫ T cell populations. They correspond to infrequently used BV families in the normal human TCR repertoire (42) . When looking at the CDR3␤ chain length profiles (Fig. 5B) , both populations showed an almost Gaussian-like curve distribution for each BV family studied with no evidence for oligoclonal expansion even in case of differential usage of a given BV (see for example the BV2 profile among the representative BV profiles shown in Fig. 5B) .
Overall, these data do not argue for a restricted Ag-driven expansion of CD4 ϩ CD25 high T cells infiltrating melanoma metastatic LNs.
Discussion
CD4
ϩ CD25 high T reg have been shown in murine models to play an important role in dominant peripheral tolerance by controlling potentially harmful autoreactive T cells. They have been also implicated recently in the down-regulation of antitumor responses in transplantable murine tumor models (15) (16) (17) . Such a role could explain the poor clinical efficiency of immunotherapeutic protocols in human tumors. Recently, it was shown that CD4 ϩ CD25 high T reg specifically express a transcription factor, Foxp3, which plays a major role in their development and function (18 -21, 26, 29) . Foxp3 is currently considered to be the most accurate marker to identify T reg (21) . Indeed, in human PBMCs, we found that Foxp3 is expressed almost exclusively by the CD4 ϩ CD25 high T cell population that is known to contain T reg (27, 28, 30, 31) . In the present study of melanoma metastatic LNs, we identified substantial Foxp3 expression among infiltrating CD4 ϩ CD25 high T lymphocytes in all the cases studied. Furthermore, such infiltrating CD4 ϩ CD25 high T cells display the phenotype of peripheral memory T cells (CD45RO ϩ CD27 ϩ ) (44) and constitutively express high levels of CD152 (CTLA-4). Functionally, CD4
ϩ CD25 high T cells do not proliferate in vitro and do not produce IL-2 or IFN-␥ upon TCR-mediated activation. They clearly suppress both the proliferation and cytokine production of infiltrating CD4 ϩ CD25
Ϫ as well as CD8 ϩ T cells in a cell-contact-dependent manner. All these features described above have been recently ascribed to human peripheral T reg (24, 25, 27, 28, 30 -33) . The fact that these cells widely inhibit both infiltrating CD4 ϩ CD25 Ϫ as well as CD8 ϩ T cells is in accordance with the observation that once activated, both mice and human T reg suppress other T cells in an Agindependent manner (13, 14) . Thus, our data reveal that CD4 ϩ CD25 high T cells found in melanoma metastatic LNs behave as T reg , suggesting that they may play an active role in downregulating local antitumor responses. Such a role for suppressive T cells has been suggested long time ago in melanoma by Mukherji and colleagues (48, 49) , who observed CD4 ϩ T cell clones with some suppressive activity from metastatic LNs. We have preliminary evidence that these infiltrating CD4 ϩ
CD25
high T cells could inhibit in vitro the proliferation of a CD8 ϩ T cell clone recognizing the tumor Ag MelanA/Mart-1. However, as mentioned above, such an observation is not surprising due to the suppressive activity of T reg independent of the specificity of the target effectors (13, 14) .
Importantly, we found that such CD4 ϩ CD25 high T reg are overrepresented in metastatic LNs and express high levels of CTLA-4, CD69, and CD27, consistent with the phenotype of activated T reg . This directly raises the question whether these cells are recruited and expanded at the tumor site from circulating T reg or from resident LN T reg . It was recently demonstrated by Fisson et al. (46) that in mice, a fraction of T reg present in normal LNs and spleen is continuously activated and is dividing in the steady-state while another fraction remains quiescent. In addition, according to what was suspected (14), Salomon's group have nicely shown that activation of LN T reg is driven by physiological sustained presentation of tissue self-Ags in draining LNs (46) . In our case, we found the presence of activated T reg in metastatic LNs, but also in tumorfree satellite LNs, as well as in two cutaneous draining LNs from healthy donors. In the cases of tumor-free and normal LNs, the observed activated T reg could well correspond to such T reg activated at the steady-state because they express Foxp3 (data not shown). In the case of metastatic LNs, the observed expansion of the T reg already present locally may be due to an increased Ag stimulation either by tumor-specific Ags or self-Ags expressed by tumor cells. In accordance with this hypothesis, the fact that CD4 ϩ CD25 high T cells in both metastatic and tumor-free LNs express a largely polyclonal repertoire does not argue for a stimulation by a limited number of Ags, but rather for a stimulation by a large panel of Ags. However, we cannot exclude that such an expansion is due to nonspecific stimulation of steady-state T reg in the context of a local suppressive microenvironment generated by invading tumor cells via immunosuppressive cytokines (as TGF-␤ or IL-10). To solve these issues of the Ag specificities of the T reg expanded at the tumor site, further studies analyzing isolated infiltrating T reg clones are needed. In favor of an Ag-driven stimulation of infiltrating T reg in melanoma, Wang's group (50) recently identified the tumor Ag LAGE-1 as the ligand recognized by some infiltrating regulatory T cell clones isolated not from metastatic LNs but from a melanoma tumor.
It is important to note that the existence of such a steady-state level of activation of LN T reg may well control the occurrence of any efficient antitumor immune response during the course of tumor development, even prior to tumor cell invasion, when tumor Ags from the primitive tumor potentially reach the draining LN via dendritic cells (51) . However, because in tumor-free satellite LNs, the in vitro T reg suppressive activity appeared to be lower than in metastatic LNs, one may predict that it is in such satellite LNs that the detection of ongoing not yet fully inhibited antitumor immune response should be easier to isolate for further immunotherapeutic approaches (3).
Tumor-infiltrating Foxp3 ϩ CD4 ϩ CD25 high T reg were found, as expected, to operate in vitro through a cell contact mechanism. However, the degree of inhibition observed was almost correlated to the secretion of IL-10 by CD4 ϩ CD25 high and also CD4 ϩ CD25 Ϫ T cells in our in vitro assay. In addition, anti-IL-10 or anti-TGF-␤ 1-3 Abs could revert this inhibition indicating that part of the mechanism may also be cytokine-dependent. However, the drastic effect of anti-TGF-␤ 1-3 Ab contrasts with the fact that CD4 ϩ CD25 high T cells were rarely found to secrete TGF-␤ 1 , the only TGF-␤ isoform detected by our ELISA. Because real-time PCR analysis did not allow us to detect any expression of either TGF-␤ 2 or TGF-␤ 3 isoforms by CD4 ϩ CD25 high T cells (data not shown), this suggests that the anti-TGF-␤ 1-3 blocking Ab may exert its effect through cell surface-bound TGF-␤1, which was recently implicated in the mediation of cell-contact-dependent immunosuppression by CD4 ϩ CD25 high T cells (52) . It is of course difficult to extrapolate in vivo the mechanisms of suppression suggested by in vitro experiments. This is well illustrated in the mice model were the mode of action of T reg in vivo remains unclear and is still largely debated (14) . To explain the in vivo suppressive activity of T reg at low CD4 ϩ CD25 high :CD4 ϩ CD25 Ϫ ratio while needing direct cell contact, several groups (53) (54) (55) (56) have shown that CD4 ϩ
high T reg may convey a suppressive activity to other CD4 ϩ T cells that was found to be contact independent and either IL-10 (55) or TGF-␤ dependent (56), a phenomenon known as infectious tolerance (57). Thus, it is possible that the cytokinedependent suppressive activity observed in our study may reflect the presence of such de novo-generated suppressive T cells. In contrast, it has been well documented that T reg with cytokine-dependent suppressive activity could be induced from mature CD4 ϩ T cells under defined conditions of Ag stimulation in the presence of immunosuppressive drugs or cytokines (28, 58, 59) . Our data suggest that Tr1/Th3-like T cells (22, 23) secreting both IL-10 and TGF-␤ could be detected in melanoma metastatic LNs among CD4 ϩ CD25 Ϫ T cells. Because melanoma cells have been described to secrete either IL-10 (60) or TGF-␤ (61), it is possible that the tumor cells themselves participate locally to the induction of such CD4 ϩ
Ϫ suppressor T cells. In addition, it is noteworthy that TGF-␤ has been shown to promote the expansion of CD4 ϩ CD25 high T reg (62) and that blockade of TGF-␤ signaling has been recently implicated in the immune-mediated eradication of tumors (63) . This suggests that melanoma cells could also use TGF-␤ secretion to induce the local expansion of Foxp3
high T reg observed in our study. Taken together, the increased proportion of infiltrating Foxp3
high T reg as well as the suppressive activity of infiltrating CD4 ϩ
Ϫ T cells support the idea that the local suppressive network is likely to be complex in metastatic melanoma and that distinct subtypes of suppressive T cells may be involved.
It has been recently shown in a murine model of Leishmania major infection that CD4 ϩ CD25 high T reg control the persistence of the parasite by suppressing, through both IL-10-dependent and IL-10-independent mechanisms, the ability of CD4 ϩ CD25 Ϫ effector T cells to eliminate the parasite (64) . In addition, the maintenance of strong resistance to reinfection, known as concomitant immunity, is also controlled by such CD4 ϩ CD25 high T reg , suggesting that the recirculating pool of memory cells is maintained while effector T cells are suppressed locally (64) . This situation strikingly parallels some features of tumor immunology where concomitant immunity is a well-known phenomenon (65) and where local immunosuppression appears to be important (10) . Further studies on melanoma patients are needed to determine whether infiltrating CD4 ϩ CD25 high T reg , as in the L. major model, effectively suppress in vivo local effector immune responses. To this respect, immunotherapeutic strategies aimed to counteract in vivo the action of T reg might provide important answers to this hypothesis and would have crucial impacts on the designing of efficient vaccination protocols for the treatment of melanoma patients.
